November 21, 2023
Gosselies, Belgium
Bioxodes closes €12 million in Series A funding round
Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage. Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023